Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Jun 29;16(6):e0252289.
doi: 10.1371/journal.pone.0252289. eCollection 2021.

Personalized prediction of disease activity in patients with rheumatoid arthritis using an adaptive deep neural network

Affiliations
Multicenter Study

Personalized prediction of disease activity in patients with rheumatoid arthritis using an adaptive deep neural network

Maria Kalweit et al. PLoS One. .

Abstract

Background: Deep neural networks learn from former experiences on a large scale and can be used to predict future disease activity as potential clinical decision support. AdaptiveNet is a novel adaptive recurrent neural network optimized to deal with heterogeneous and missing clinical data.

Objective: We investigate AdaptiveNet for the prediction of individual disease activity in patients from a rheumatoid arthritis (RA) registry.

Methods: Demographic and disease characteristics from over 9500 patients and 65.000 visits from the Swiss Quality Management (SCQM) database were used to train and evaluate the network. Patient characteristics, clinical and patient reported outcomes, laboratory values and medication were used as input features. DAS28-BSR served as a target to predict active RA and future numeric individual disease activity by classification and regression.

Results: AdaptiveNet predicted active disease defined as DAS28-BSR >2.6 at the next visit with an overall accuracy of 75.6% (SD +- 0.7%) and a sensitivity and specificity of 84.2% (SD +- 1.6%) and 61.5% (SD +- 3.6%), respectively. Prediction performance was significantly higher in patients with a disease duration >3 years and positive rheumatoid factor. Regression allowed forecasting individual DAS28-BSR values with a mean squared error (MSE) of 0.9 (SD +- 0.05). This corresponds to a 8% deviation between estimated and real DAS28-BSR values. Compared to linear regression, random forest and support vector machines, AdaptiveNet showed an increased performance of over 7% in MSE. Medication played a minor role in the prediction of RA disease activity.

Conclusion: AdaptiveNet has a superior capacity to predict numeric RA disease activity compared to classical machine learning architectures. All investigated models had limitations in low specificity.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interest.

Figures

Fig 1
Fig 1. Deep neural network architecture (AdaptiveNet).
All visits and medication adjustments are projected to latent vectors of the same size using encoder networks ϕvisits and ϕmeds. Latent vectors are sorted according to dates and fed into a Long Short-term Memory (LSTM) to create a latent vector describing the full patient history. The final prediction is computed by the network module ρ, exploiting the patient history with general patient information.
Fig 2
Fig 2. Classification performance of AdaptiveNet to predict active disease (DAS28-BSR>2.6) in different patient subsets shown by Receiver Operating Characteristic Curves.
Accuracy and corresponding AUCs are indicated in Table 1.
Fig 3
Fig 3. Examples of true disease activity and corresponding predictions of AdaptiveNet by regression analysis.
Predictions are made step to step from the current to next visit.

References

    1. Pierreisnard A, Issa N, Barnetche T, Richez C, Schaeverbeke T. Meta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexate. Joint Bone Spine. Jul 2013;80(4):386–92. doi: 10.1016/j.jbspin.2012.09.023 - DOI - PubMed
    1. Smolen JS, Landewé R, Bijlsma J, et al.. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. Jun 2017;76(6):960–977. doi: 10.1136/annrheumdis-2016-210715 - DOI - PubMed
    1. Joo YB, Kim Y, Park Y, et al.. Biological function integrated prediction of severe radiographic progression in rheumatoid arthritis: a nested case control study. Arthritis Res Ther. Oct 2017;19(1):244. doi: 10.1186/s13075-017-1414-x - DOI - PMC - PubMed
    1. Cuppen BV, Welsing PM, Sprengers JJ, et al.. Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. Rheumatology (Oxford). May 2016;55(5):826–39. doi: 10.1093/rheumatology/kev421 - DOI - PubMed
    1. Roodenrijs NMT, van der Goes MC, Welsing PMJ, et al.. Is prediction of clinical response to methotrexate in individual rheumatoid arthritis patients possible? A systematic literature review. Joint Bone Spine. Jan 2020;87(1):13–23. doi: 10.1016/j.jbspin.2019.04.002 - DOI - PubMed

Publication types

Substances